Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium

Rhea-AI Summary

Akebia Therapeutics (NASDAQ: AKBA) announced that CEO John P. Butler, CFO/Chief Business Officer Erik Ostrowski, and CMO Dr. Steven Burke will hold one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026 in New York.

No company presentations are planned; management will discuss commercial products, and data and information from Akebia’s recent R&D Day showcasing its clinical-stage kidney disease pipeline.

Argus Apr 7 session

+4.55% close to close Open Argus

Details

News Market Reaction – AKBA

On Apr 7, the day this news came out, AKBA closed 4.55% above the previous close.

Data tracked by StockTitan Argus for the Apr 7 session.

Market Context

This announcement centers on Akebia holding one‑on‑one investor meetings at a biotech symposium on A...

Analysis

This announcement centers on Akebia holding one‑on‑one investor meetings at a biotech symposium on April 14, 2026, following an R&D Day that highlighted its kidney disease pipeline. Historically, similar communication events and board or compensation updates had limited or mixed price impact, while earnings and pipeline data drove stronger reactions. Investors may focus on how management frames revenue trends, cash of $184.8M from prior filings, and progress of mid‑stage kidney programs in future data‑driven updates.

Key Figures

Symposium date: April 14, 2026 Announcement date: April 7, 2026

Symposium date

April 14, 2026

Raymond James 2026 Biotech Innovation Symposium meetings

Announcement date

April 7, 2026

Press release publication date for investor meetings

Historical Context

5 past events · Latest: 2026-04-01

5 events

1. 2026-04-01

   Board change

   24h Move

   -2.1%

   New director Philip Vickers appointed while another director retired.

2. 2026-03-19

   R&D day announcement

   24h Move

   +0.0%

   Scheduled virtual R&D Day to review kidney disease pipeline.

3. 2026-03-03

   Conference participation

   24h Move

   -3.2%

   Management fireside chat at Leerink Partners healthcare conference.

4. 2026-03-02

   Inducement grants

   24h Move

   -3.2%

   Stock option inducement awards to newly hired employees.

5. 2026-02-26

   Earnings and pipeline

   24h Move

   +9.1%

   Strong 2025 revenue growth, narrower net loss, and pipeline progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Erik Ostrowski, Chief Financial and Chief Business Officer, and Dr. Steven Burke, Chief Medical Officer, will participate in one-on-one meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14 in New York, NY. Company presentations are not planned at the Symposium.

During meetings, management will discuss its commercial products, and data and other information shared during Akebia’s recent R&D Day that showcased its robust pipeline of clinical stage kidney disease programs.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com  

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who from Akebia (AKBA) will attend the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026?

Akebia will send CEO John P. Butler, CFO/Chief Business Officer Erik Ostrowski, and CMO Dr. Steven Burke. According to the company, they will hold one-on-one investor meetings in New York to discuss commercial products and recent R&D Day data.

Will Akebia (AKBA) give a public presentation at the Raymond James 2026 Biotech Innovation Symposium?

No, Akebia will not give a public presentation at the symposium. According to the company, management plans only one-on-one meetings to discuss commercial products and information from its recent R&D Day.

What topics will Akebia management discuss with investors at the Raymond James 2026 symposium?

Management will discuss Akebia’s commercial products and clinical-stage kidney disease pipeline data. According to the company, conversations will include information shared during its recent R&D Day showcasing the pipeline.

When and where will Akebia (AKBA) hold investor meetings during the Raymond James 2026 event?

Investor meetings are scheduled for Tuesday, April 14, 2026, in New York, NY. According to the company, meetings are one-on-one at the Raymond James 2026 Biotech Innovation Symposium.

How can investors learn about the Akebia (AKBA) data discussed at the Raymond James 2026 symposium?

Investors can review materials from Akebia’s recent R&D Day to learn the discussed data and pipeline updates. According to the company, management will reference that R&D Day information during one-on-one meetings.